Journal article 604 views 44 downloads
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes
Diabetic Medicine, Volume: 37, Issue: 2, Pages: 219 - 228
Swansea University Author: Steve Bain
-
PDF | Version of Record
Copyright 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License
Download (376.84KB)
DOI (Published version): 10.1111/dme.14180
Abstract
AimsTo revisit the data analysis used to inform National Institute of Health and Care Excellence (NICE) NG17 guidance for initiating basal insulin in adults with type 1 diabetes mellitus (diabetes).MethodsWe replicated the data, methodology and analysis used by NICE diabetes in the NG17 network meta...
Published in: | Diabetic Medicine |
---|---|
ISSN: | 0742-3071 1464-5491 |
Published: |
Wiley
2020
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa52764 |
first_indexed |
2019-11-18T13:14:14Z |
---|---|
last_indexed |
2023-01-11T14:30:03Z |
id |
cronfa52764 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2022-12-02T19:27:54.1377548</datestamp><bib-version>v2</bib-version><id>52764</id><entry>2019-11-18</entry><title>A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2019-11-18</date><deptcode>MEDS</deptcode><abstract>AimsTo revisit the data analysis used to inform National Institute of Health and Care Excellence (NICE) NG17 guidance for initiating basal insulin in adults with type 1 diabetes mellitus (diabetes).MethodsWe replicated the data, methodology and analysis used by NICE diabetes in the NG17 network meta-analysis (NMA). We expanded this data cohort to a more contemporary data set (extended 2017 NMA) and restricted the studies included to improve the robustness of the data set (restricted 2017 NMA) and in a post hoc analysis, changed the index comparator from neutral protamine Hagedorn (NPH) insulin twice daily to insulin detemir twice daily.ResultsThe absolute changes in HbA1c were similar to those reported in the NG17. However, all 95% credible intervals for change in HbA1c point estimates crossed the line of null effect, except for detemir twice daily (in the NICE and extended 2017 NMAs) and NPH four times daily. In the detemir twice-daily centred post hoc analysis, the 95% credible intervals for change in HbA1c crossed the line of null effect for all basal therapies, except NPH.ConclusionsIn NG17, comparisons of basal insulins were based solely on efficacy of glycaemic control. Many of the trials used in this analysis were treat-to-target, which minimize differences in HbA1c. In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations.</abstract><type>Journal Article</type><journal>Diabetic Medicine</journal><volume>37</volume><journalNumber>2</journalNumber><paginationStart>219</paginationStart><paginationEnd>228</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0742-3071</issnPrint><issnElectronic>1464-5491</issnElectronic><keywords/><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-02-01</publishedDate><doi>10.1111/dme.14180</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>Sanofi</funders><projectreference/><lastEdited>2022-12-02T19:27:54.1377548</lastEdited><Created>2019-11-18T09:48:31.4664748</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>1</order></author><author><firstname>M.</firstname><surname>Feher</surname><order>2</order></author><author><firstname>M.</firstname><surname>Fisher</surname><order>3</order></author><author><firstname>N.</firstname><surname>Hex</surname><orcid>0000-0002-6181-9429</orcid><order>4</order></author><author><firstname>K. C. S.</firstname><surname>Lee</surname><order>5</order></author><author><firstname>J.</firstname><surname>Mahon</surname><order>6</order></author><author><firstname>D.</firstname><surname>Russell‐Jones</surname><order>7</order></author><author><firstname>H.</firstname><surname>Schou</surname><order>8</order></author><author><firstname>E. G.</firstname><surname>Wilmot</surname><orcid>0000-0002-8698-6207</orcid><order>9</order></author><author><firstname>M.</firstname><surname>Baxter</surname><order>10</order></author></authors><documents><document><filename>52764__25995__f467eae65258415595be57e3e2fd5865.pdf</filename><originalFilename>52764.pdf</originalFilename><uploaded>2022-12-02T19:26:44.5097975</uploaded><type>Output</type><contentLength>385883</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Copyright 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
2022-12-02T19:27:54.1377548 v2 52764 2019-11-18 A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2019-11-18 MEDS AimsTo revisit the data analysis used to inform National Institute of Health and Care Excellence (NICE) NG17 guidance for initiating basal insulin in adults with type 1 diabetes mellitus (diabetes).MethodsWe replicated the data, methodology and analysis used by NICE diabetes in the NG17 network meta-analysis (NMA). We expanded this data cohort to a more contemporary data set (extended 2017 NMA) and restricted the studies included to improve the robustness of the data set (restricted 2017 NMA) and in a post hoc analysis, changed the index comparator from neutral protamine Hagedorn (NPH) insulin twice daily to insulin detemir twice daily.ResultsThe absolute changes in HbA1c were similar to those reported in the NG17. However, all 95% credible intervals for change in HbA1c point estimates crossed the line of null effect, except for detemir twice daily (in the NICE and extended 2017 NMAs) and NPH four times daily. In the detemir twice-daily centred post hoc analysis, the 95% credible intervals for change in HbA1c crossed the line of null effect for all basal therapies, except NPH.ConclusionsIn NG17, comparisons of basal insulins were based solely on efficacy of glycaemic control. Many of the trials used in this analysis were treat-to-target, which minimize differences in HbA1c. In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations. Journal Article Diabetic Medicine 37 2 219 228 Wiley 0742-3071 1464-5491 1 2 2020 2020-02-01 10.1111/dme.14180 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Sanofi 2022-12-02T19:27:54.1377548 2019-11-18T09:48:31.4664748 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Steve Bain 0000-0001-8519-4964 1 M. Feher 2 M. Fisher 3 N. Hex 0000-0002-6181-9429 4 K. C. S. Lee 5 J. Mahon 6 D. Russell‐Jones 7 H. Schou 8 E. G. Wilmot 0000-0002-8698-6207 9 M. Baxter 10 52764__25995__f467eae65258415595be57e3e2fd5865.pdf 52764.pdf 2022-12-02T19:26:44.5097975 Output 385883 application/pdf Version of Record true Copyright 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License true eng http://creativecommons.org/licenses/by-nc-nd/4.0/ |
title |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
spellingShingle |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes Steve Bain |
title_short |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
title_full |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
title_fullStr |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
title_full_unstemmed |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
title_sort |
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes |
author_id_str_mv |
5399f4c6e6a70f3608a084ddb938511a |
author_id_fullname_str_mv |
5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain |
author |
Steve Bain |
author2 |
Steve Bain M. Feher M. Fisher N. Hex K. C. S. Lee J. Mahon D. Russell‐Jones H. Schou E. G. Wilmot M. Baxter |
format |
Journal article |
container_title |
Diabetic Medicine |
container_volume |
37 |
container_issue |
2 |
container_start_page |
219 |
publishDate |
2020 |
institution |
Swansea University |
issn |
0742-3071 1464-5491 |
doi_str_mv |
10.1111/dme.14180 |
publisher |
Wiley |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
document_store_str |
1 |
active_str |
0 |
description |
AimsTo revisit the data analysis used to inform National Institute of Health and Care Excellence (NICE) NG17 guidance for initiating basal insulin in adults with type 1 diabetes mellitus (diabetes).MethodsWe replicated the data, methodology and analysis used by NICE diabetes in the NG17 network meta-analysis (NMA). We expanded this data cohort to a more contemporary data set (extended 2017 NMA) and restricted the studies included to improve the robustness of the data set (restricted 2017 NMA) and in a post hoc analysis, changed the index comparator from neutral protamine Hagedorn (NPH) insulin twice daily to insulin detemir twice daily.ResultsThe absolute changes in HbA1c were similar to those reported in the NG17. However, all 95% credible intervals for change in HbA1c point estimates crossed the line of null effect, except for detemir twice daily (in the NICE and extended 2017 NMAs) and NPH four times daily. In the detemir twice-daily centred post hoc analysis, the 95% credible intervals for change in HbA1c crossed the line of null effect for all basal therapies, except NPH.ConclusionsIn NG17, comparisons of basal insulins were based solely on efficacy of glycaemic control. Many of the trials used in this analysis were treat-to-target, which minimize differences in HbA1c. In the NMAs, statistical significance was severely undermined by the wide credible intervals. Despite these limitations, point estimates of HbA1c were used to rank the insulins and formed the basis of NG17 guidance. This study queries whether such analyses should be used to make specific clinical recommendations. |
published_date |
2020-02-01T02:05:08Z |
_version_ |
1821369285808750592 |
score |
11.04748 |